Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.41 |
| ▸ | CPT1A | P50416 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1643975 | 0.90 | ADORA2A (0.49) | HRH3ADORA2AADORA1TNK2HSD17B10 | |
| SCHEMBL12727999 | 0.79 | ADORA2A (0.48) | HRH3ADORA2AADORA1CPT1AATR | |
| SCHEMBL1644546 | 0.78 | ADORA2A (0.56) | HRH3ADORA2AADORA1ADORA3ADORA2B | |
| Ammonia Solution, Strong SCHEMBL3121909 | 0.78 | RAB9A (0.52) | ADORA2AADORA1HSD17B10NPC1RAB9A | |
| SCHEMBL1643134 | 0.77 | SCN9A (0.43) | ADORA2AADORA1TNK2KMT2AALDH1A1 | |
| SCHEMBL1643667 | 0.75 | TNK2 (0.44) | ADORA2AADORA1TNK2KMT2ASMN1; SMN2 | |
| SCHEMBL1643965 | 0.75 | ADORA2A (0.48) | ADORA2AADORA1ADORA2BTNK2KMT2A | |
| SCHEMBL1642908 | 0.73 | SCN9A (0.40) | ADORA2AADORA1TNK2KMT2AALDH1A1 | |
| SCHEMBL12771476 | 0.73 | ABL1 (0.41) | HRH3ADORA2AADORA1NPC1RAB9A | |
| SCHEMBL1644452 | 0.72 | NPC1 (0.46) | HSD17B10NPC1RAB9AKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098301-A1 | Pyrimidine Derivatives for Treatment of Hyperproliferative Disorders | BAYER HEALTHCARE LLC (US) | 2011-04-28 | — | — | US | disclosed |
| US-20100075967-A1 | PYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| US-7678804-B2 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER HEALTHCARE LLC (US) | 2010-03-16 | — | — | US | disclosed |
| US-7582645-B2 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| US-20070117817-A1 | 4-{3-[(2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy}-N-methylpyridine-2-carboxamide;anticarcinogenic agents; breast cancer; antitumor agents; respiratory system disorders; urogenital disorders; gastrointestinal disorders; skin disorders; glandular disorders; lymphomas; leukemia; cytolysis | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-24 | — | — | US | disclosed |
| US-20050277640-A1 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075967-A1 | PYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | TYMP, DPYD, CCNA2 | HRH3 502/4885ADORA2A 809/4885ADORA1 1231/4885 |
| US-20070117817-A1 | 4-{3-[(2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy}-N-methylpyridine-2-carboxamide;anticarcinogenic agents; breast cancer; antitumor agents; respiratory system disorders; urogenital disorders; gastrointestinal disorders; skin disorders; glandular disorders; lymphomas; leukemia; cytolysis | CCNA2, MALT1, TPD52L2 | HRH3 215/4885ADORA2A 762/4885ADORA1 1106/4885 |
| US-20050277640-A1 | Pyrimidine derivatives for treatment of hyperproliferative disorders | TYMP, DPYD, CCNA2 | HRH3 502/4885ADORA2A 809/4885ADORA1 1231/4885 |
| US-20110098301-A1 | Pyrimidine Derivatives for Treatment of Hyperproliferative Disorders | DPYD, TYMP, TYMS | HRH3 1729/4885ADORA2A 1487/4885ADORA1 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.